Biopharmaceutical leader in the development of treatments for rare diseases
Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.  

Education about transparency of drug pricing and reimbursement in France. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.Education about the Pre-Existing Condition Insurance Plan (PCIP) in the Affordable Care Act and legislative efforts to redirect funding from other sources into the program. H.R. 1416: Cancer Patient Protection Act of 2013.

Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.
TRD - Trade (domestic/foreign) HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
W STRATEGIES, LLC
1455 Pennsylvania Avenue, NW, Suite 400, Washington, DC, 20004, US
DARREN WILLCOX DARREN WILLCOX DARREN WILLCOX